Innoviva マネジメント

マネジメント基準チェック /44

Innovivaの CEO はPavel Raifeldで、 May2020年に任命され、の在任期間は 4.5年です。の年間総報酬は$ 868.65Kで、 55.8%給与と44.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.019%を直接所有しており、その価値は€ 214.59K 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と6.8年です。

主要情報

Pavel Raifeld

最高経営責任者

US$868.6k

報酬総額

CEO給与比率	55.8%
CEO在任期間	4.5yrs
CEOの所有権	0.02%
経営陣の平均在職期間	2.9yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Innoviva の収益と比較して、Pavel Raifeld の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$65m
Jun 30 2024	n/a	n/a	US$145m
Mar 31 2024	n/a	n/a	US$181m
Dec 31 2023	US$869k	US$485k	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

報酬と市場: Pavelの総報酬 ($USD 868.65K ) は、 German市場 ($USD 1.46M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Pavelの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Pavel Raifeld (40 yo)

4.5yrs

在職期間

US$868,648

報酬

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Pavel Raifeld	Chief Executive Officer	4.5yrs	US$868.65k	0.019% € 214.6k
Stephen Basso	Chief Financial Officer	1.3yrs	US$1.18m	データなし
Marianne Zhen	Chief Accounting Officer & Secretary	6.3yrs	US$924.21k	0.073% € 838.9k
Patricia Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics	less than a year	データなし	データなし

2.9yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: HVEの経営陣は経験豊富であると考えられます ( 2.9年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jules Haimovitz	Independent Director	6.8yrs	US$446.02k	0.19% € 2.1m
Sapna Srivastava	Independent Director	1.8yrs	US$547.11k	0.041% € 468.2k
Derek Small	Independent Director	less than a year	データなし	データなし
Odysseas Kostas	Independent Director	6.9yrs	US$331.18k	0.17% € 2.0m
Sarah Schlesinger	Independent Director	6.8yrs	US$367.25k	0.17% € 1.9m
Mark DiPaolo	Independent Director	6.8yrs	US$396.59k	0.17% € 1.9m

6.8yrs

平均在職期間

52.5yo

平均年齢

経験豊富なボード: HVEの取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Innoviva マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44